BiotechTube
preclinics

preclinics

Munich, Germany· Est.
preclinics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

preclinics is a privately held, Germany-based preclinical CRO founded in 2017, offering a broad portfolio of research services, biological products, and custom instruments. Its core model integrates contract research across small molecules, biologics, and devices with proprietary capabilities in camelid VHH antibody generation and specialized in vivo assays like the REVOLYZER®. The company has expanded through subsidiaries, including a research farm for animal immunizations and an Italian hub for microbial expression, positioning itself as a diversified partner for early-stage biopharma and veterinary research.

Drug DeliveryMedical Devices

Technology Platform

Integrated preclinical CRO platform offering antibody services (specializing in camelid VHH generation), pharmacokinetic/efficacy testing, custom research instrument fabrication (e.g., REVOLYZER®), and biological product production. Combines in vivo facilities, molecular biology labs, and a dedicated research farm.

Opportunities

Growing demand for single-domain antibody (VHH) discovery services presents a key growth vector.
Expansion into Italy via preclinics Italia provides access to new academic and biotech networks and enhances microbial expression capabilities.
The integrated model of services, products, and instruments allows for cross-selling and capturing more value per client.

Risk Factors

Operational reliance on animal-based services subjects the company to stringent welfare regulations and potential shifts toward in vitro alternatives.
Intense competition in the preclinical CRO market from larger, well-capitalized players could pressure margins and client acquisition.
Execution risk associated with recent international expansion and integration of the Italian subsidiary.

Competitive Landscape

preclinics competes in the fragmented preclinical CRO market, facing competition from large global CROs (e.g., Charles River, Labcorp) and numerous niche specialists. Its differentiation lies in the integrated offering of camelid VHH services, proprietary instruments, and biological products from its own farm—a combination not commonly found in a single entity. It competes on specialization and flexibility rather than scale.

More companies in Small Molecule Drugs →More companies in Germany →